Drugs / ARALAST NP
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01183468 | Oct 2010 → Jul 2013 | type 1 diabetes mellitus | National Institute of Allergy and Infectious Diseases (NIAID) | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01183455 | Oct 2010 → Aug 2014 | type 1 diabetes mellitus | National Institute of Allergy and Infectious Diseases (NIAID) | Withdrawn | No outcome recorded Stop: Business |
| Phase 31 trial | ||||||
| Phase 3 | NCT02722304 | Nov 2016 → Sep 2018 | alpha 1-antitrypsin deficiency, chronic obstructive pulmonary disease | Baxalta now part of Shire | Terminated | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT04440488 | Mar 2021 → Sep 2025 | alpha 1-antitrypsin deficiency, chronic obstructive pulmonary disease | Shire | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ARALAST NP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04440488 ↗ |
| Known as | Alpha 1-Proteinase Inhibitor Human | “Alpha 1-Proteinase Inhibitor Human” NCT01183455 ↗ |
| Modality | Protein / enzyme biologic | “an alpha-1 proteinase inhibitor (human)” NCT01183455 ↗ |
| Route | Intravenous | “Participants will receive IV infusions of Aralast NP (90mg/kg) once a week for 12 weeks.” NCT01183455 ↗ |